Djavan Bob, Dianat Seyed Saeid, Kazzazi Amir
New York University, Department of Urology, New York, USA.
Patient Relat Outcome Meas. 2011 Jul;2:71-9. doi: 10.2147/PROM.S13062. Epub 2011 Mar 31.
Benign prostatic hyperplasia, the fourth most commonly diagnosed medical condition in the elderly, is a major underlying cause of lower urinary tract symptoms in men. Medical therapy is usually the first therapeutic option. Combination therapy is increasingly used for better symptom relief and outcome.
We searched the literature using the MEDLINE database for the efficacy of combination therapy in men with benign prostatic hyperplasia in terms of symptom improvement and impact on quality of life.
Combination therapy with dutasteride and tamsulosin not only provides better symptom improvement and improved urinary flow rate, but is also associated with a more favorable impact on quality of life and patient satisfaction with treatment than monotherapy. Combination therapy also reduces the risk of events related to disease progression, such as acute urinary retention and benign prostatic hyperplasia-related surgery.
Combination therapy with dutasteride and tamsulosin is highly efficacious as medical therapy for benign prostatic hyperplasia in patients with moderate-to-severe lower urinary tract symptoms.
良性前列腺增生是老年人中第四大最常被诊断出的病症，是男性下尿路症状的主要潜在原因。药物治疗通常是首选治疗方案。联合治疗越来越多地用于更好地缓解症状和改善预后。
我们使用MEDLINE数据库检索文献，以了解联合治疗对良性前列腺增生男性患者在症状改善和对生活质量影响方面的疗效。
度他雄胺和坦索罗辛联合治疗不仅能更好地改善症状和提高尿流率，而且与单药治疗相比，对生活质量和患者对治疗的满意度有更有利的影响。联合治疗还降低了与疾病进展相关事件的风险，如急性尿潴留和良性前列腺增生相关手术。
度他雄胺和坦索罗辛联合治疗作为中重度下尿路症状患者良性前列腺增生的药物治疗非常有效。
